Transitioning from Insulin to Oral Hypoglycemic Agents in Post-Operative Patients

Decision Algorithm Based on Pre-Admission Treatment and HbA1c

For Type 2 diabetic patients previously on OHAs only, with HbA1c <8%, resume previous oral antidiabetic agents at the same doses after 48 hours, provided renal clearance is >30 mL/min for all OADs and >60 mL/min for metformin 1, 2
The American Diabetes Association recommends that patients with HbA1c 8-9% continue basal insulin glargine at discharge, with a dose titration protocol, and arrange consultation with a diabetologist for therapy intensification 1, 2
For patients with HbA1c >9% or blood glucose >11 mmol/L, maintain the full basal-bolus insulin regimen and do not transition to OHAs alone 1, 2

Before resuming any oral hypoglycemic agents, verify renal clearance, with metformin requiring creatinine clearance >60 mL/min and all other OADs requiring >30 mL/min 1, 2
The American College of Clinical Endocrinologists recommends that patients with inadequate renal function continue insulin therapy and arrange endocrinology follow-up 1, 2

Continue capillary blood glucose monitoring, with pre-prandial testing before each meal to guide any remaining bolus insulin dosing, and monitor for hypoglycemia symptoms 3
The Endocrine Society recommends measuring capillary blood glucose immediately if any symptoms suggestive of hypoglycemia occur, and administering glucose immediately for blood glucose <3.3 mmol/L (60 mg/dL) even without symptoms 3

Provide clear written instructions, including specific medication names, doses, and timing, blood glucose monitoring schedule, hypoglycemia recognition and treatment plan, and follow-up appointment timing based on HbA1c level 1, 2, 3
Arrange appropriate follow-up, with HbA1c <8%: treating physician at 1 month, HbA1c 8-9%: diabetologist consultation, and HbA1c >9%: urgent diabetologist consultation before discharge 1, 2